A clinical research on the amount of liver fat when treated with the combination therapy of interferon and DFPP (Double filtration plasmapheresis) measured by MRS(Magenetic Resonance Spectroscopy) - Clinical research on the amount of liver fat when treated with the combination therapy of interferon and DFPP.

Kanazawa University Hospital Department of Gastroenterology0 个研究点目标入组 20 人开始时间: 2010年1月1日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Patients ever experienced shock during extracorporeal therapy. 2) Patients who has previous history of hypersensitivity for biological pruducts such as interferon and vaccines. 3) Patients who are now being administered shoo-saikoto. 4) Patients with autoimmune hepatitis. 5) Patients ever experienced a hyper-sensitivity against nucleoside analogues( aciclovir, ganciclovir, vidarabine etc). 6) Patients with uncontrollable cardiac disorder( myocardial infarction, heart failure, arrhythmia) . 7) Patients with hemoglobinopathy (thalassemia, drepanocytic anemia). 8) Patients with chronic renal failure, or whose creatine clearances are under 50mL/min. 9) Patients with serious depression, serious mental state such as suicidal ideation, suicide attempt, or with those histories. 10) Patients with severe hepatic dysfunction. 11) Patients whose platelet numbers are less than 50,000/L upon registration or before the first DFPP. 12) Patients whose fibrinogen levels are less than 100mg/dL upon registration or before the first DFPP. 13) Patients installed or planted with metals( including metal powder) , cardiac pacemaker, implantable nerve stimulator, implantable defibrillator, or cerebrospinal drain tube. 14) Patients who had participated in other clinical researches or clinical trials. 15) Pregnant women, nursing women, or possible pregnant. 16) Additionally, patients who had been judged as unsuitable for this clinical research by the doctors.

发起方

Kanazawa University Hospital Department of Gastroenterology